Q-omics provides the consensus-scored SLC22A23 profile across patient tissues and cancer cell-line models. SLC22A23 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SLC22A23 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, SLC22A23 RNA expression shows 20,417 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, THCA, and UVM as cancer lineages where SLC22A23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A23 survival associations across molecular data types. SLC22A23 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A23 RNA expression–survival associations across cancer types. High SLC22A23 expression shows unfavorable associations in KIRP, LGG and KICH, but favorable associations in KIRC, LUAD and UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SLC22A23 RNA expression.
This table summarizes SLC22A23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC22A23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A23 shows lower tumor expression in THCA, COAD, KIRP and KIRC and higher tumor expression in LIHC and HNSC. The THCA box plot shows higher SLC22A23 RNA expression in normal versus tumor tissue (log2 FC = −1.551, t-test p < 0.001).
This table shows molecular features associated with SLC22A23 in patient tissues and cancer cell lines. In patient samples, SLC22A23 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
